凌意

Lingyi Biotech is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of AAV-based gene therapies for rare and metabolic diseases. The company utilizes its proprietary viral vector platform to design treatments that offer potential one-time cures for genetic disorders such as Fabry disease and Gaucher disease. Its lead program, LY-M001, has advanced into the IND-enabling phase, targeting the restoration of enzyme function in patients with Fabry disease. Lingyi Biotech also explores gene therapy applications for neurodegenerative conditions, including GBA-related Parkinson's disease. Supported by prominent venture capital firms, the company is building a robust pipeline and manufacturing infrastructure to accelerate the delivery of genetic medicines.